An update on redifferentiation strategies for radioactive iodine-refractory differentiated thyroid carcinoma
Authors:
- 4 September 2024
- journal article
- review article
- Published by Springer Nature in Endocrine
- Vol. 87 (1) , 1-10
Abstract
Purpose Although most patients with differentiated thyroid carcinoma (DTC) have an excellent prognosis, a subset will experience radioactive iodine refractory (RAI-R) disease, associated with recurrence, distant metastases and worse prognosis. In recent years, redifferentiation has emerged as an attractive approach for patients with RAI-R DTC, a strategy to induce iodine uptake in RAI-R DTC tumor cells and ultimately prolong time to initiation of systemic therapy. Methods An overview and critical appraisal of the existing literature on redifferentiation will be presented in this review under the lens of the genotype-specific targeted therapy administered with redifferentiation intent. Results/conclusions Due to the significant heterogeneity across studies, it will be key to harmonize research methodology and support future larger, multicenter prospective trials in order to identify the most suitable candidates for this therapeutic strategy.Keywords
Funding Information
- NIH (5K12AR084230-21)
- American Thyroid Association
- Sperling Family Fellowship
This publication has 55 references indexed in Scilit:
- Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma statusJournal of Endocrinological Investigation, 2024
- Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid CarcinomasJAMA Oncology, 2023
- 1657P Clinical and molecular profiles of radioiodine refractory differentiated thyroid cancerAnnals of Oncology, 2022
- Overview of the 2022 WHO Classification of Thyroid NeoplasmsEndocrine Pathology, 2022
- Larotrectinib-Enhanced Radioactive Iodine Uptake in Advanced Thyroid CancerNew England Journal of Medicine, 2020
- Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013JAMA, 2017
- Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiationCancer Gene Therapy, 2015
- Integrated Genomic Characterization of Papillary Thyroid CarcinomaCell, 2014
- Radioiodine therapy for papillary and follicular thyroid carcinomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002
- Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical resultsExperimental and Clinical Endocrinology & Diabetes, 1996